Skip to main content
Igor Wolfgang Blau on Muck Rack

Igor Wolfgang Blau

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Igor Wolfgang

Contact Igor Wolfgang, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT

|
By Ryszard Swoboda, Myriam Labopin, Nicolaus Kröger, Matthias Stelljes, Thomas Schroeder, Peter Dreger, Gesine Bug, Andrew McDonald, Montserrat Rovira, Igor Wolfgang Blau, Desiree Kunadt, Regis de Latour, Werner Rabitsch, Matthias Eder, Marie Therèse Rubio, Alexandros Spyridonidis, Zinaida Perić, Sebastian Giebel, Mohamad Mohty Verified, Fabio Ciceri, Tülay Özçelik
| Nature Verified
Abstract There are very limited data on treosulfan (Treo)-based conditioning before allogeneic hematopoietic stem cell transplantation (alloHSCT) in acute lymphoblastic leukemia. We aimed to compare fludarabine with Treo (FluTreo) or total body irradiation (FluTBI) in this setting. The final matched-pair analysis included ALL patients transplanted in complete remission after FluTreo (n = 153) or FluTBI (n = 431). The median patient age was 56.5 and 54.1 years, respectively.
Open in Who Shared Issue with article?

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia

|
By Alexandros Spyridonidis, Allain Thibeault Ferhat, Jacques Emmanuel Galimard, Thomas Schroeder, Regis de Latour, Nicolaus Kröger, Didier Blaise, Matthias Stelljes, Matthias Eder, Tobias Gedde-Dahl, Igor Wolfgang Blau, Ibrahim Yakoub-Agha, Edouard Forcade, Anne Huynh, Francesca Kinsella, Hélène Labussiere-Wallet, Jakob Passweg, Robert Zeiser, Mohamed Nabil Houhou, Bipin N. Savani, Roni Shouval, Jurjen Versluis, Mohamad Mohty Verified, Fabio Ciceri, Annalisa Ruggeri
| Nature Verified
Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) can cure acute leukemia, but relapse and non-relapse mortality restrict its success. Existing models focus on single prognostic areas and are not designed to predict leukemia-free survival (LFS), the outcome that best reflects allo-HCT’s curative intent.
Open in Who Shared Issue with article?

Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies

|
By Daniel E. Furst, Sarah Flossdorf, Francis Ayuk, Thomas Schroeder, Matthias Stelljes, Robert Zeiser, Peter Dreger, Matthias Eder, Igor Wolfgang Blau, Johannes Schetelig, Arne Brecht, Andreas Burchert, Matthias Edinger, Hubert Schrezenmeier, Hartmut Döhner, Sandra Schmeller, Katharina Fleischhauer, Nicolaus Kröger, Elisa M. Sala, German I.V.F Registry, Andrea Gantner, Svenja Labuhn, Sophie Mannes, Verena Wais
| Nature Verified
Abstract The selection of the best available donor is crucial for patients’ outcome after allogeneic stem cell transplantation (allo-SCT). In the absence of fully Human leucocyte antigen (HLA) -matched donors, mismatched unrelated donor (9/10-MUD) or haploidentical donor (haplo) can be considered. No consensus has been reached on the best alternative and large real-world data are warranted to support decisional processes.
Open in Who Shared Issue with article?
See all 3 articles